Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy (ENFORCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04833426
Recruitment Status : Not yet recruiting
First Posted : April 6, 2021
Last Update Posted : August 10, 2021
Sponsor:
Collaborator:
Besins Healthcare
Information provided by (Responsible Party):
Canisius-Wilhelmina Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Sexual dysfunction is a common side effect of radical prostatectomy (RP) and has a significant negative impact on quality of life. With age the testosterone level in men declines; around 30% of men over 70 years of age meet the criteria of testosterone deficiency (TD). The negative impact of both TD and RP on sexual performance are likely to add up. The aim of this study is to assess the efficacy and safety of testosterone replacement therapy (TRT) on functional and oncological outcomes in testosterone deficient men following RP for prostate cancer (PCa).

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Hypogonadism Testosterone Deficiency Drug: Testosterone gel Drug: Placebo Phase 3

Detailed Description:

Rationale: Radical prostatectomy (RP) is currently the most common treatment for non-metastatic prostate cancer (PCa). Two frequent side effects of this procedure are urinary incontinence and erectile dysfunction, both having a significant negative impact on quality of life.

Additionally, it is known that with age the testosterone level in men declines. This does not lead to symptoms in all men (asymptomatic testosterone deficiency). Both testosterone deficiency (TD) and radical prostatectomy are well-established to have a significant negative impact on sexual performance and are likely to add up in patients with a low testosterone following RP.

Objective: The aim of this study is to assess the effect of testosterone replacement therapy (TRT) on functional and oncological outcomes in testosterone deficient men following RP for PCa.

Study design: This study is a phase 3 prospective, randomized, placebo-controlled, single-blind clinical trial. Study population: All men over 18 years old diagnosed with non-metastatic prostate cancer who are scheduled for RP within three months as primary treatment, can be prescreened for inclusion. Prior to the RP, serum testosterone will be determined. Subsequently, within six weeks after the RP, serum testosterone will be determined again and patients will be screened for inclusion. If necessary, a third measurement of testosterone will be done. Eligible patients meet the criteria for TD and other inclusion criteria. Intervention: Patients will be randomized for testosterone replacement therapy (TRT) or placebo as a daily administered topical gel starting within 8 weeks after RP. Patients will receive TRT or placebo for one year following RP and will be monitored for another year for functional outcomes and for four more years to establish 5-year biochemical recurrence (BCR) free survival.

Main study parameters/endpoints:

The primary study endpoint is a clinically relevant (12 points or more) difference in the EPIC-26 domain for sexual functioning 12 months after RP in favor of testosterone deficient men receiving TRT compared with testosterone deficient men receiving placebo. Secondary endpoints include: urinary incontinence score, hormonal functioning score and BCR-free survival. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The number of visits and blood drawings are equal to standard of care follow-up after RP, with the exception of two or three extra blood samples at the first prescreening visit and within six weeks following RP. We ask patients to remain with their hospital for 24 months after RP for follow-up and to complete online questionnaires for the given visits. The five-year biochemical recurrence (BCR) free survival will be obtained through patient's medical records and if insufficient, through the Dutch Cancer Registry (NKR). Patients who receive TRT or placebo can experience local side-effects such as itching, rash and/or irritation at the site of application. In addition, patients who receive TRT can experience systemic sideeffects are gain of weight, hot flashes, acne and an increase in red blood count level. Furthermore, TRT might improve sexual functioning, urinary continence, hormonal functioning and BCR-free survival, but this is not certain and is subject of research in this study.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
Estimated Study Start Date : September 1, 2021
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : April 2027

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Testosterone therapy
Daily application of two pump auctions of 16.2mg/ml testosterone gel. Dosage may be altered depending on clinical response
 Drug: Testosterone gel
Topical gel containing testosterone
Placebo Comparator: Placebo therapy
Daily application of two pump auctions of placebo gel.
 Drug: Placebo
Topical gel without active substance
Other Name: Placebo gel


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Clinically relevant (≥12 points) difference in the EPIC-26 sexual functioning domain score, 12 months after radical prostatectomy between groups. [ Time Frame: 12 months ]
    Functional recovery after radical prostatectomy will be assessed by EPIC-26 questionnaire, a Patient Reported Outcome Measure (PROM). Patients will be asked to complete this questionnaire online.


Secondary Outcome Measures :
  1. Clinically relevant (≥12 points) difference in the EPIC-26 sexual functioning domain score 3 months after radical prostatectomy between groups. [ Time Frame: 3 months ]
    Clinical relevance (>12 points) for sexual function domain score as measured by EPIC-26.

  2. Clinically relevant (≥12 points) difference in the EPIC-26 sexual functioning domain score 24 months after radical prostatectomy between groups. [ Time Frame: 24 months ]
    Clinical relevance (>12 points) for sexual function domain score as measured by EPIC-26.

  3. Clinically relevant (≥9 points) difference in the EPIC-26 urinary incontinence domain score, 12 months after radical prostatectomy between groups. [ Time Frame: 12 months ]
    Clinical relevance (>9 points) for Urinary incontinence domain score as measured by EPIC-26.

  4. Clinically relevant (≥9 points) difference in the EPIC-26 urinary incontinence domain score, 24 months after radical prostatectomy between groups. [ Time Frame: 24 months ]
    Clinical relevance (>9 points) for Urinary incontinence domain score as measured by EPIC-26.

  5. Clinically relevant (≥6 points) difference in the EPIC-26 for hormonal functioning domain score, 12 months after radical prostatectomy between groups. [ Time Frame: 12 months ]
    Clinical relevance (>6 points) for hormonal functioning domain score as measured by EPIC-26.

  6. Clinically relevant (≥6 points) difference in the EPIC-26 for hormonal functioning domain score, 24 months after radical prostatectomy between groups. [ Time Frame: 24 months ]
    Clinical relevance (>6 points) for hormonal functioning domain score as measured by EPIC-26.

  7. Difference in biochemical recurrence rate between groups. [ Time Frame: 5 years ]
    Biochemical recurrence (BCR) is defined as the occurrence of measurable (>0.1 ng/ml) prostate specific antigen (PSA), during routinely follow-up up to five years after surgery, determined at two different occasions with at least one week between them.The BCR-rate between the placebo and control group will be compared to determine the influence of testosterone therapy on BCR.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Unmeasurable PSA after RP
  2. pT2-pT3a after RP
  3. ISUP 1-3 regardless of surgical margins
  4. ISUP 4-5 with negative surgical margins
  5. At least one-sided nerve-sparing procedure
  6. Baseline score sexual functioning domain of ≥ 40 points (EPIC-26)

Exclusion Criteria:

  1. Metastatic disease (cN1/M1)
  2. pT3b or pT4 after RP
  3. Prior treatment for PCa
  4. Prior TRT
  5. Medical history of male breast- or liver carcinoma
  6. Uncontrolled hypertension
  7. General contra-indication for TRT
  8. Allergy for components in TRT
  9. Use of vitamin K-antagonists
  10. BMI > 30
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04833426


Contacts
Layout table for location contacts
Contact: Diederik Baas, MSc +31243658190 d.baas@cwz.nl

Locations
Layout table for location information
Netherlands
Jeroen Bosch Hospital
's-Hertogenbosch, Netherlands
Contact: Rob Wijn, MD         
Netherlands Cancer Institute
Amsterdam, Netherlands
Contact: Pim van Leeuwen, MD, PhD         
Catharina Hospital
Eindhoven, Netherlands
Contact: Eric Vrijhof, MD, PhD         
Zuyderland
Heerlen, Netherlands
Contact: Max Bruins, MD, PhD         
St. Antonius Hospital
Nieuwegein, Netherlands
Contact: Harm van Melick, MD, PhD         
Radboud university medical center
Nijmegen, Netherlands
Contact: Michiel Sedelaar, MD, PhD         
Sponsors and Collaborators
Canisius-Wilhelmina Hospital
Besins Healthcare
Investigators
Layout table for investigator information
Principal Investigator: Diederik Somford, MD, PhD Canisius-Wilhelmina Hospital
  Study Documents (Full-Text)

Documents provided by Canisius-Wilhelmina Hospital:
Study Protocol and Statistical Analysis Plan  [PDF] December 8, 2020

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Canisius-Wilhelmina Hospital
ClinicalTrials.gov Identifier: NCT04833426    
Other Study ID Numbers: NL7436209120
2020-003012-27 ( EudraCT Number )
2020-6874 ( Other Identifier: CMO Arnhem-Nijmegen )
First Posted: April 6, 2021    Key Record Dates
Last Update Posted: August 10, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Canisius-Wilhelmina Hospital:
Prostate cancer
Prostatectomy
Hypogonadism
Testosterone deficiency
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Hypogonadism
Gonadal Disorders
Endocrine System Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
 Neoplasms
Prostatic Diseases
Testosterone
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs